Moneycontrol News
Cadila Healthcare, part of Zydus Cadila on Tuesday, said it has received establishment inspection report (EIR) from US FDA for its formulation manufacturing facility at Pharma SEZ near Ahmedabad.
The receipt of EIR indicates the successful closure of the inspection points raised by the US drug regulator
The SEZ unit underwent US FDA audit from January 16 to 24, 2017.
Shares of Cadila declined 0.21 percent and were trading at Rs.500 on BSE at 12.32 pm, the benchmark Sensex dropped 0.76 and was trading 31,496.74 points.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
